SKYE

Skye Bioscience Inc

0.9900

Nov 06 • 10:58 AM ET -0.0500 (-4.81%)

Healthcare Biotechnology USA Nano NASD

Peers: TVRD GYRE PLRX AVLN RNTX GALT VCRE FBLG IVA SVRA

Index	-
Market Cap	4.38M
Enterprise Value	-5.50M
Income	-50.49M
Sales	0.00M
Book/sh	-0.11
Cash/sh	2.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Nov 26, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	0.44
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.95
Current Ratio	0.95
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-10.18
EPS next Y	-6.75
EPS next Q	-1.14
EPS this Y	47.52%
EPS next Y	-13.96%
EPS next 5Y	1.68%
EPS past 3/5Y	45.62% 28.34%
Sales past 3/5Y	- -
EPS Y/Y TTM	-19.07%
Sales Y/Y TTM	-
EPS Q/Q	38.85%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-13.30% -

Insider Own	32.76%
Insider Trans	-43.46%
Inst Own	18.32%
Inst Trans	7.90%
ROA	-159.80%
ROE	-233.87%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-30.77%
SMA50	-39.50%
SMA200	-78.89%
Trades

Shs Outstand	4.39M
Shs Float	2.98M
Short Float	4.71%
Short Ratio	1.55
Short Interest	0.14M
52W High	12.80 -92.26%
52W Low	1.04 -4.81%
Volatility	11.47% 8.56%
ATR (14)	0.14
RSI (14)	24.15
Beta	3.17
Rel Volume	0.31
Avg Volume	90.69K
Volume	7,538

Perf Week	-22.66%
Perf Month	-41.07%
Perf Quarter	-76.76%
Perf Half Y	-85.66%
Perf YTD	-83.49%
Perf Year	-91.86%
Perf 3Y	-92.93%
Perf 5Y	-99.42%
Perf 10Y	-99.90%
Recom	3.00
Target Price	16.00
Prev Close	1.04
Price	0.99
Change %	-4.81%

Consensus

Hold

Avg. Price Target

$16.00

Implied Upside

+1,516.2%

Analysts7incl. previous ratings

Rating Distribution5 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 06, 2025	Downgrade	CCraig Hallum	Buy → Hold	$2	+102.0%
Oct 06, 2025	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$2	+102.0%
Aug 15, 2025	Initiated	EEvercore ISI	Outperform	$10	+910.1%
Feb 28, 2025	Initiated	WWilliam Blair	Outperform
Sep 30, 2024	Initiated	BScotiabank	Sector Outperform	$20	+1,920.2%
Sep 10, 2024	Initiated	JJMP Securities	Mkt Outperform	$15	+1,415.2%
Jul 09, 2024	Initiated	CCraig Hallum	Buy	$18	+1,718.2%
May 23, 2024	Initiated	CCantor Fitzgerald	Overweight	$21	+2,021.2%
Apr 12, 2024	Initiated	OOppenheimer	Outperform	$25	+2,425.3%

Aug-17-26 01:32PM	Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Fibrex ... (GuruFocus.com) -17.23%
Aug-14-26 09:33AM	Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings (GlobeNewswire) -7.30%
Jul-17-26 02:55PM	The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea (Yahoo Finance)
May-20-26 07:00AM	Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 (GlobeNewswire) +6.04%
May-12-26 01:33PM	UPDATE - Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update (GlobeNewswire) -7.56%
04:01PM	Loading…
May-11-26 04:01PM	Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Apr-07-26 07:00AM	Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit (GlobeNewswire)
Apr-02-26 07:00AM	Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development (GlobeNewswire)
Mar-11-26 09:04PM	Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ... (GuruFocus.com) -9.70%
Mar-10-26 04:01PM	Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) +10.33%
Mar-05-26 07:00AM	Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 (GlobeNewswire)
Feb-02-26 01:26PM	Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year (Benzinga) -7.92%
07:00AM	Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide (GlobeNewswire)
Jan-29-26 07:00AM	Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference (GlobeNewswire)
Jan-21-26 07:00AM	Skye Bioscience to Present Poster at Keystone Obesity Conference (GlobeNewswire)
03:32AM	Loading…
Jan-14-26 03:32AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire)
Jan-12-26 07:00AM	Skye Provides 2026 Corporate Outlook (GlobeNewswire)
Jan-06-26 09:00AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - SKYE (PR Newswire) +17.73%
Jan-05-26 07:00AM	Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity (PR Newswire)
Dec-29-25 01:25AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire)
Dec-19-25 02:56PM	Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE. (Business Wire) -6.99%
Dec-11-25 07:44AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire)
Dec-08-25 02:55AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire)
Dec-02-25 09:00AM	Investors in Skye Bioscience, Inc. Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - SKYE (PR Newswire) -8.26%
Dec-01-25 03:40AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire) -7.63%
Nov-26-25 08:00AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SKYE (Business Wire)
Nov-24-25 07:00AM	Skye Bioscience to Participate in Upcoming Investment Conferences (Newsfile) +11.59%
Nov-11-25 12:01AM	Skye Bioscience Inc (SKYE) Q3 2025 Earnings Call Highlights: Promising Study Results and ... (GuruFocus.com)
Nov-10-25 04:01PM	Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update (GlobeNewswire) -7.19%
Nov-05-25 07:05AM	Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain (GlobeNewswire) +6.34%
07:00AM	Loading…
07:00AM	Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025 (GlobeNewswire)
Oct-07-25 11:32AM	SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal (Zacks) -12.63%
Oct-06-25 07:00AM	Skye Bioscience Reports Topline CBeyond Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial (GlobeNewswire) -60.00%
06:09AM	Skye shares crash as obesity drug falls short in key study (BioPharma Dive)
Sep-19-25 02:19PM	Could This New Drug Be The Safer Way To Fight Obesity? (Benzinga)
07:00AM	Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting (GlobeNewswire)
Sep-04-25 07:00AM	Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model (GlobeNewswire) +11.61%
Sep-02-25 07:00AM	Skye Completes 26-week Treatment Phase in Phase 2a CBeyond Study (GlobeNewswire)
Aug-27-25 07:00AM	Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond Phase 2a Topline Clinical Data Readout (GlobeNewswire)
Aug-21-25 07:00AM	Skye Bioscience to Participate in Upcoming Investment and Medical Conferences (GlobeNewswire)
Aug-08-25 07:00AM	Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ... (GuruFocus.com)
Aug-07-25 04:01PM	Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire) -8.74%
Jul-30-25 07:00AM	Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025 (GlobeNewswire)
Jul-06-25 04:01AM	Skye Bioscience Highlights Nimacimab's Promise in Obesity Treatment, Anticipates Phase 2a Data (Insider Monkey)
Jun-23-25 07:00AM	Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions (GlobeNewswire) +32.87%
Jun-22-25 06:15AM	Analysts Predict Up to ~590% Spike for These 2 Strong Buy Penny Stocks (TipRanks)
Jun-17-25 07:00AM	Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions (GlobeNewswire)
May-23-25 11:13AM	3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies (Zacks) -8.21%
May-22-25 07:00AM	Skye Bioscience to Participate in Upcoming Investment Conferences (GlobeNewswire) -6.33%
May-19-25 05:00AM	Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab (GlobeNewswire) +14.97%
May-13-25 04:05PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.37%
07:00AM	Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity (GlobeNewswire)
May-09-25 03:40AM	Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Promising Trial Progress and ... (GuruFocus.com)
May-08-25 04:01PM	Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity (GlobeNewswire)
May-07-25 07:00AM	Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 (GlobeNewswire)
Apr-29-25 07:00AM	Skye Bioscience to Participate in May Investment and Medical Conferences (GlobeNewswire)
Apr-25-25 08:06PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-16-25 07:50AM	A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value (Seeking Alpha) -7.60%
Apr-15-25 07:00AM	Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model (GlobeNewswire) +30.53%
Apr-14-25 07:00AM	Skye Bioscience to Conduct Meetings at Piper Sandler Conference (GlobeNewswire) -7.09%
Mar-20-25 09:59PM	Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period (SeekingAlpha) -5.50% +19.05%
09:58PM	Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
10:00AM	Here are the major earnings after the close today (SeekingAlpha)
Mar-19-25 05:35PM	Skye Bioscience Q4 2024 Earnings Preview (SeekingAlpha) -12.66%
Mar-14-25 07:00AM	Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025 (GlobeNewswire)
Feb-27-25 06:00PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.34%
Feb-24-25 07:00AM	Skye Bioscience to Participate in SXSW Session on Obesity (GlobeNewswire)
Feb-20-25 07:00AM	Skye Bioscience to Present at TD Cowen Health Care Conference (GlobeNewswire)
Feb-04-25 07:00AM	Skye Bioscience Announces Participation in February Conferences (GlobeNewswire)
Jan-13-25 07:00AM	Skye Bioscience Provides 2025 Look Ahead and Year in Review (GlobeNewswire)
Dec-19-24 07:00AM	Skye Bioscience to Present at J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-18-24 07:00AM	Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences (GlobeNewswire) -7.88%
Nov-15-24 07:45AM	Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond (TipRanks) -10.16%
Nov-14-24 07:00AM	Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor (GlobeNewswire)
Nov-07-24 04:01PM	Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Nov-04-24 07:00AM	Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model (GlobeNewswire)
Nov-01-24 07:00AM	Skye Bioscience to Announce Third Quarter 2024 Results (GlobeNewswire) +6.11%
Oct-29-24 07:00AM	Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board (GlobeNewswire)
Oct-21-24 07:00AM	Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences (GlobeNewswire)
Sep-23-24 07:00AM	Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan (GlobeNewswire) +11.15%
Sep-03-24 07:00AM	Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer (GlobeNewswire)
Aug-26-24 07:00AM	Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences (GlobeNewswire) +15.29%
Aug-23-24 06:45PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.69%
Aug-22-24 07:00AM	Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity (GlobeNewswire)
Aug-09-24 05:59PM	Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) -9.42%
Jul-24-24 07:30AM	Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND Phase 2 Trial of Nimacimab for Obesity (GlobeNewswire)
06:00AM	Skye Bioscience Hosts Virtual KOL Event, "Metabolic Rewiring with CB1 Inhibition," and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints (GlobeNewswire)
Jul-11-24 07:15AM	Skye Bioscience to Host Virtual KOL Event, Metabolic Rewiring with CB1 Inhibition, on July 24th (GlobeNewswire) +6.90%
07:00AM	Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab (GlobeNewswire)
Jul-03-24 07:00AM	Skye Bioscience Appoints Dr. Karen Smith to Board of Directors (GlobeNewswire)
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
07:00AM	Skye Bioscience Added to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-25-24 07:00AM	Skye BioScience Participating in Piper Sandler Virtual Obesity Day (GlobeNewswire) -6.19%
Jun-10-24 08:22AM	Skye Bioscience ends eye disease R&D efforts after glaucoma drug's phase 2 fail (FierceBiotech.com) -8.78%
07:00AM	Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program (GlobeNewswire)
Jun-03-24 07:00AM	Skye Bioscience to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-10-24 07:00AM	Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting (GlobeNewswire) -6.21%
May-07-24 11:59AM	Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program (News Direct)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schwab Andrew J.	Director	Sep 23 '26	Sale	1.61	119,379	192,200	0	Sep 24 04:31 PM
Schwab Andrew J.	Director	Sep 22 '26	Sale	1.65	28,700	47,355	4,528	Sep 24 04:31 PM
5AM Partners VII, LLC	10% Owner	Sep 23 '26	Sale	1.61	119,379	192,200	0	Sep 24 04:29 PM
5AM Partners VII, LLC	10% Owner	Sep 22 '26	Sale	1.65	28,700	47,355	4,528	Sep 24 04:29 PM
Schwab Andrew J.	Director	Sep 16 '26	Sale	1.91	33,892	64,734	5,616	Sep 18 06:39 PM
5AM Partners VII, LLC	10% Owner	Sep 16 '26	Sale	1.91	33,892	64,734	5,616	Sep 18 06:37 PM
Schwab Andrew J.	Director	Aug 18 '26	Sale	0.38	300,000	114,000	55,663	Aug 20 05:59 PM
Schwab Andrew J.	Director	Aug 19 '26	Sale	0.35	68,140	23,849	55,254	Aug 20 05:59 PM
Schwab Andrew J.	Director	Aug 20 '26	Sale	0.32	7,700	2,464	55,208	Aug 20 05:59 PM
5AM Partners VII, LLC	10% Owner	Aug 18 '26	Sale	0.38	300,000	114,000	55,663	Aug 20 05:57 PM
5AM Partners VII, LLC	10% Owner	Aug 19 '26	Sale	0.35	68,140	23,849	55,254	Aug 20 05:57 PM
5AM Partners VII, LLC	10% Owner	Aug 20 '26	Sale	0.32	7,700	2,464	55,208	Aug 20 05:57 PM

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the business of research and development activities related to developing medicine for obesity and metabolic diseases. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

PresidentMr. Punit S. Dhillon B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SKYE

Skye Bioscience Inc

Upgrade your Finviz experience